LY3841136
Sponsors
Eli Lilly and Company
Conditions
End Stage Kidney DiseaseHealthyHepatic InsufficiencyKidney DiseaseKidney Failure, ChronicObesityOverweightRenal Impairment
Phase 1
A Study of LY3841136 in Healthy and Overweight Participants
CompletedNCT05295940
Start: 2022-03-30End: 2024-01-25Updated: 2024-04-01
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
CompletedNCT06297616
Start: 2024-04-15End: 2025-11-21Updated: 2026-01-16
A Study of LY3841136 in Overweight and Obese Participants
CompletedNCT06345066
Start: 2024-04-03End: 2025-09-29Updated: 2025-10-15
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
RecruitingNCT07401862
Start: 2026-02-10End: 2027-03-01Target: 36Updated: 2026-06-04
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Active, not recruitingNCT07426380
Start: 2026-02-24End: 2026-10-01Target: 28Updated: 2026-08-19
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RecruitingNCT06143956
Start: 2023-11-17End: 2028-02-01Target: 1481Updated: 2026-09-08
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Active, not recruitingNCT06603571
Start: 2024-09-20End: 2026-08-01Updated: 2026-07-17